A next generation cardio system, the xCELLigence RTCA CardioECR system, has been introduced to fill the need for more predictive preclinical assays for cardiac liability. The system combines impedance and multi electrode array (MEA) technology with a pacing function. The platform allows simultaneous cardiomyocyte contractility and field potential measurement. Designed to be placed in a standard tissue culture incubator with physiological temperature, CO2 level and humidity, allowing better controlled assays with both short-term and long-term measurements in real-time. It allows for a deeper assessment of mechanism of toxicity. ACEA Biosciences
Print this page
Related